Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Alfuzosin 是选择性和竞争性的α1肾上腺素受体拮抗剂,可用于良性前列腺增生(BPH)的研究。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
2 mg | ¥ 225 | 现货 | ||
5 mg | ¥ 424 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 649 | 现货 |
产品描述 | Alfuzosin, a quinazoline derivative, is a selective and competitive antagonist of the α1 adrenergic receptor, primarily used to manage benign prostatic hyperplasia (BPH). It effectively targets and mitigates alpha1-adrenoceptor-mediated contraction across prostatic tissues, the prostatic capsule, bladder base, and proximal urethra, reducing muscular tone and easing symptoms linked to BPH. Clinical studies indicate alfuzosin's superiority over placebo for up to 6 months, sustained efficacy with long-term use (up to 30 months), and comparability to prazosin, another alpha 1-adrenoceptor antagonist, in treating BPH symptoms. Recommended oral doses of 7.5 to 10 mg/day, divided, position alfuzosin as a potential first-line treatment for mild to moderate BPH, especially for patients with significant dynamic obstruction. Additionally, alfuzosin serves as an alternative to prostatectomy for patients unable to undergo surgery, offering symptomatic relief during the waiting period for surgical intervention. |
分子量 | 389.45 |
分子式 | C19H27N5O4 |
CAS No. | 81403-80-7 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Alfuzosin 81403-80-7 Inhibitor inhibitor inhibit